In particular, rat HER2 cross-reactivity was built into the phage display and in vitro selection campaign to facilitate functional evaluations in a fully immunocompetent syngeneic rat model of a medium/low rHER2-expressing breast cancer. The gene discussed is ERBB2; the disease is breast cancer.